Thrombocytopenia is a common medical problem for which the main treatment is platelet
transfusion. Given the increasing use of platelets and the declining donor population …

Thrombocytopenia that results from chemotherapy has become an increasingly important
issue in the treatment of cancer and remains a difficult clinical problem. The identification of …

PURPOSE: To explore the influence of dose and schedule on the ability of pegylated
recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) to …

To evaluate a potential therapeutic role for megakaryocyte growth and development factor
(MGDF) in myelodysplastic syndromes (MDS) we compared the in vitro response of normal …

Alternatives to platelet transfusions are important in preventing the adverse events
associated with platelet transfusions. The use of platelet alternatives has not been …

The discovery of platelet growth factors raised expectations that an effective method for
abrogating thrombocytopenia would soon be available in the clinic. The cytokines initially …

Platelets are fundamental to hemostasis in the body. More than 90 years ago, Wright first
proposed that platelets were shed from megakaryocytes (1), which are themselves derived …

Thrombocytopenia is a common problem that affects both oncology and non-oncology
patients. Thrombocytopenia is occasionally encountered withconventional chemotherapy …

Thrombopoietin (TPO) was the name proposed by Kelemen in 1958 for the hematopoietic
growth factor (HGF) presumed to regulate platelet production like erythropoietin (EPO) …

It was recognized soon after the discovery of the ligand to c-mpl that this was the long sought
after central regulator of megakaryocytopoiesis and thrombopoiesis 1. The native or …